WG
SYRE icon

Winton Group’s Spyre Therapeutics SYRE Stock Holding History

Winton Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-528
Closed -$101K – 1758
2019
Q3 		$101K Buy
+528
New +$103K ﹤0.01% 1464
2019
Q2 		– Sell
-479
Closed -$96K – 1275
2019
Q1 		$96K Buy
+479
New +$99.8K ﹤0.01% 1033

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winton Group's SYRE Position: Q4 2019 in Review

Winton Group sold out of Spyre Therapeutics (SYRE) in Q4 2019, closing a stake of 528 shares — an estimated $101K sold.

Winton Group first reported a position in SYRE in Q1 2019 and held it in 2 quarters. The position peaked at $101K in Q3 2019. 68 funds tracked by Wall St. Rank hold SYRE as of Q4 2019.

  • Winton Group reported no remaining Spyre Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 528 Spyre Therapeutics shares in Q4 2019, an estimated $101K.
  • Winton Group first reported a position in Spyre Therapeutics in Q1 2019 and held it in 2 quarters.
  • Winton Group's Spyre Therapeutics position peaked at $101K in Q3 2019.
  • 68 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.